Copyright
©The Author(s) 2024.
World J Clin Oncol. Aug 24, 2024; 15(8): 1078-1091
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1078
Published online Aug 24, 2024. doi: 10.5306/wjco.v15.i8.1078
Table 1 IC50 value of kakkatin and 6-(hept-6-yn-1-yloxy)-3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one on tumor Cells (μM)
| Drug | SMMC-7721 cells | MGC803 cells |
| Cisplatin | 17.54 | 20.83 |
| Kakkatin | 76.93 | 38.24 |
| The 6-(hept-6-yn-1-yloxy)-3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one | 2.50 | 39.51 |
Table 2 The docking energy of 6-(hept-6-yn-1-yloxy)-3-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one and genes
| Complex | Gene | Affinity (kcal/mol) |
| 7bvq-molecule1-1 | ADRB1 | -9.6 |
| 1so2-molecule1-1 | PDE3B | -9.5 |
| P22694-molecule1-1 | PRKACB | -7.4 |
| 7 Lfc-molecule1-1 | NFKB1 | -5.9 |
- Citation: Jiang YY, Dong HH, Zhou WT, Luo JZ, Wei X, Huang YQ. Preparation of kakkatin derivatives and their anti-tumor activity. World J Clin Oncol 2024; 15(8): 1078-1091
- URL: https://www.wjgnet.com/2218-4333/full/v15/i8/1078.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i8.1078